News Formal

Amgen’s stock jumps premarket after earnings beat and company again raises guidance

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.

Amgen Inc.’s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. The company posted net income of $1.730 billion, or $3.22 a share, for the quarter, down from $2.143 billion, or $3.98 a share, in the year-earlier period. Adjusted per-share earnings came to $4.96, well ahead of the $4.68 FactSet consensus. Revenue climbed to $6.903 billion from $6.652 billion, close to the $6.

923 billion FactSet consensus. Sales of the company’s Enbrel, which is used to treat autoimmune diseases, fell 6%. Repatha, a treatment for high cholesterol, saw sales climb 31%, while osteoporosis treatment Prolio saw sales rise 14%. Amgen is now expecting full-year adjusted EPS of $18.20 to $18.80 and revenue of $28.0 billion to $28.4 billion. The FactSet consensus is for EPS of $18.36 and revenue of $27.6 billion. The stock has gained 0.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 3. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Healthpeak Properties and Physicians Realty to combine in $21 all-stock merger of equalsCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »

S&P Global upgrades Ford’s rating and restores it to investment gradeCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »